Clinical course and prognosis of patients with hepatocellular carcinoma and haemophilia

Matsuda Noritaka; Imai Norihiro; Yokoyama Shinya; Yamamoto Kenta; Ito Takanori; Ishizu Yoji; Honda Takashi; Okamoto Shuichi; Kanematsu Takeshi; Suzuki Nobuaki; Matsushita Tadashi; Ishigami Masatoshi; Kawashima Hiroki

タイトル	en Clinical course and prognosis of patients with hepatocellular carcinoma and haemophilia
作成者	en Matsuda, Noritaka en Imai, Norihiro en Yokoyama, Shinya en Yamamoto, Kenta en Ito, Takanori en Ishizu, Yoji en Honda, Takashi en Okamoto, Shuichi en Kanematsu, Takeshi en Suzuki, Nobuaki en Matsushita, Tadashi en Ishigami, Masatoshi en Kawashima, Hiroki
アクセス権	open access
権利情報	en "This is a non-final version of an article published in final form in (Matsuda, Noritaka; Imai, Norihiro; Yokoyama, Shinya; Yamamoto, Kenta; Ito, Takanori; Ishizu, Yoji; Honda, Takashi; Okamoto, Shuichi; Kanematsu, Takeshi; Suzuki, Nobuaki; Matsushita, Tadashi; Ishigami, Masatoshi; Kawashima, Hiroki. Clinical course and prognosis of patients with hepatocellular carcinoma and haemophilia. European Journal of Gastroenterology & Hepatology 35(10):p 1211-1215, October 2023. DOI: 10.1097/MEG.0000000000002628)."
内容注記	Abstract en Introduction: Although patients with haemophilia are known to develop hepatocellular carcinoma (HCC) at a lower age than patients without, there are few reports on the clinical course and prognosis of HCC. Aim: We aimed to investigate the clinical course and prognosis of patients with HCC and haemophilia. Methods: Twenty-two patients with haemophilia, who were initially diagnosed with HCC between 2003 and 2021, were included. Their clinical courses and prognoses were retrospectively analysed. The results were compared with those of the 24th Nationwide Follow-up Survey of Primary Liver Cancer. Results: All 22 patients were male; of these, 20 patients had haemophilia A, and 2 had haemophilia B. The mean age of diagnosis was 63 years (range 45–78 years) which is lower than the mean of 72 years reported in the Nationwide Survey. The mean diameter of the largest tumour was 30 mm (range 11–70 mm), and 18 tumours (82%) were solitary at the initial diagnosis. Standard treatments for HCC were performed in all patients. Sixty-one transarterial chemoembolisation, 28 RFA, 10 hepatectomies, and 2 radiation treatments were performed, and molecular-targeted agents were administered to 5 patients during their clinical courses. No deaths were associated with complications of HCC treatments. The median survival time after initial treatment was 6.4 years (range 0.9–18.7 years) which did not differ much from the median survival time of 5.8 years in the Nationwide Survey. Conclusion: Standard treatment for HCC could improve the prognosis of patients with HCC and haemophilia.
出版者	en Wolters Kluwer Health
日付	Available2024-10-01 , Issued2023-10
言語	eng
資源タイプ	journal article
出版タイプ	AM
資源識別子	HDL http://hdl.handle.net/2237/0002008907 , URI https://nagoya.repo.nii.ac.jp/records/2008907
関連	isVersionOf DOI https://doi.org/10.1097/MEG.0000000000002628
収録誌情報	PISSN 0954-691X en European Journal of Gastroenterology & Hepatology 巻35 号10 開始ページ1211 終了ページ1215
ファイル	fulltext https://nagoya.repo.nii.ac.jp/record/2008907/files/EJGH_RE_NI0628.pdf 473 KB (application/pdf) Available2024-10-01
コンテンツ更新日時	2024-10-04